Top Banner Top Banner

Conclusions21 (MetaOpinion™)
Antiangiogenic drugs hold great promise for the future of breast cancer therapy. Numerous studies are ongoing to better define which types of patients can most benefit from these cutting edge therapies. For example, the identification of certain markers of angiogenesis from tumor tissue or blood samples is one area of special interest. This strategy is already being used successfully to tailor treatment for breast cancer patients whose tumors are positive for hormonal receptors and HER-2.

Other avenues of basic research continue to advance our knowledge of the complex biological mechanisms underlying tumor angiogenesis. The results of this research could translate into improved outcomes for patients with breast cancer in the months and years to come. Finally, patients are encouraged to enroll in clinical trials, which often offer the best access to cutting edge new therapies.


Last updated March 1, 2012